Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00073892 · ClinicalTrials.gov registry record · Phase 1

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by Cellxpert Biotechnology.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
5
Study locations

NCT00073892 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin) that has completed, run by Cellxpert Biotechnology. The registered enrollment target is 44 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (91% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00073892, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), has completed, sponsored by Cellxpert Biotechnology.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
5
Study locations

Study Summary

RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific Melanoma (Skin)

Interventions

  • DRUG PI-88

Study Locations (5)

Colorado

  • University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora

Queensland

  • Princess Alexandra Hospital - Brisbane

South Australia

  • Queen Elizabeth Hospital - Woodville

Victoria

  • Alfred Hospital - Melbourne

Western Australia

  • Sir Charles Gairdner Hospital - Perth - Perth

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2004-01
Est. Completion 2005-11
Phase Phase 1

Sponsor

Cellxpert Biotechnology

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00073892

The ClinicalTrials.gov registry entry for NCT00073892 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (91% lower). The listed sponsor is Cellxpert Biotechnology, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which PI-88 is the first listed.

NCT00073892 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Colorado, Queensland, South Australia.

Frequently Asked Questions

What is clinical trial NCT00073892 about?

NCT00073892 is a clinical study titled "PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma". RATIONALE: PI-88 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of PI-88 in treating patients who have an advanced malignancy (cancer) or stage IV melanoma.

What is the current status of trial NCT00073892?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2004-01. Estimated completion is 2005-11.

What conditions does trial NCT00073892 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Melanoma (Skin).

What interventions are being tested in trial NCT00073892?

The interventions under investigation include: PI-88 (DRUG).

Who is sponsoring clinical trial NCT00073892?

This trial is sponsored by Cellxpert Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00073892 being conducted?

This trial has 5 study locations across Colorado, Queensland, South Australia, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Melanoma (Skin)

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.